Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

Recent & Breaking News (TSXV:SBM)

Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067

Canada NewsWire February 6, 2019

/R E P E A T -- Sirona Biochem releases CEO Letter to Shareholders/

Canada NewsWire January 30, 2019

Sirona Biochem releases CEO Letter to Shareholders

Canada NewsWire January 30, 2019

Sirona Biochem's SGLT2 Inhibitor in Testing for Animal Health

Canada NewsWire December 11, 2018

Sirona Biochem Begins Proof of Efficacy Clinical Trial for TFC-1067

Canada NewsWire November 6, 2018

Sirona Biochem Engages Consultant for Japanese Market Penetration

GlobeNewswire October 17, 2018

Sirona Biochem Announces Close of Financing and Extension of Convertible Notes

GlobeNewswire October 16, 2018

Sirona Biochem to Present at the 2018 Arctic Circle Assembly

GlobeNewswire October 11, 2018

Sirona Biochem CEO’s Report on Progress

GlobeNewswire September 28, 2018

Sirona Biochem Receives Positive Safety Data for Lead Skin-Lightener in Preparation for Clinical Trial in the US

GlobeNewswire September 26, 2018

Sirona Biochem Receives $500,000 USD Milestone Payment from Wanbang Biopharmaceuticals

GlobeNewswire August 28, 2018

Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial

GlobeNewswire July 12, 2018

Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension

GlobeNewswire May 14, 2018

Sirona Biochem to Exhibit at the Shanghai China Beauty Expo 2018

GlobeNewswire April 30, 2018

Sirona Biochem Announces Chief Scientific Officer to Present at Adaptations in Polar Environments and Biomimicry

MarketWire Canada February 2, 2018

Sirona Biochem Announces Development of Anti-Wrinkle Treatment and Update from J.P. Morgan Healthcare Conference

MarketWire Canada January 31, 2018

Sirona Biochem Announces Receipt of $500,000 US Milestone Payment

MarketWire Canada January 29, 2018

Sirona Biochem Announces SGLT2 IND Submission Milestone

MarketWire Canada December 29, 2017

Sirona Biochem Announces Results of AGM & CEO Update

MarketWire Canada December 19, 2017

Sirona Biochem Announces Grant of Stock Options

MarketWire Canada November 20, 2017